| scholarly article | Q13442814 |
| P50 | author | Luigi Naldini | Q16574299 |
| Eugenio Montini | Q42157497 | ||
| Daniela Cesana | Q55190317 | ||
| Stefania Merella | Q83609835 | ||
| P2093 | author name string | Jacopo Sgualdino | |
| Laura Rudilosso | |||
| P2860 | cites work | Overlapping enhancer/promoter and transcriptional termination signals in the lentiviral long terminal repeat | Q21245196 |
| Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia | Q24618997 | ||
| Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration | Q28242708 | ||
| Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1 | Q28290118 | ||
| Integrating mRNA processing with transcription | Q28610124 | ||
| HIV-1 integration in the human genome favors active genes and local hotspots | Q29618457 | ||
| Nonsense-mediated RNA decay regulation by cellular stress: implications for tumorigenesis. | Q33739414 | ||
| Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma | Q33992803 | ||
| Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease | Q34094502 | ||
| Ending the message: poly(A) signals then and now | Q34213955 | ||
| RNA 3' readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy | Q34342598 | ||
| Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. | Q34508425 | ||
| Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy | Q35011497 | ||
| Retroviral insertional mutagenesis: past, present and future | Q36318150 | ||
| DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer | Q36676474 | ||
| Insertional mutagenesis in gene therapy and stem cell biology | Q36833839 | ||
| Insertional gene activation by lentiviral and gammaretroviral vectors. | Q37033273 | ||
| The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy | Q37143395 | ||
| High-throughput insertional mutagenesis screens in mice to identify oncogenic networks | Q37492234 | ||
| SpliceDB: database of canonical and non-canonical mammalian splice sites | Q38661897 | ||
| Effect of the internal promoter on insertional gene activation by lentiviral vectors with an intact HIV long terminal repeat | Q39735611 | ||
| Risk assessment in skin gene therapy: viral-cellular fusion transcripts generated by proviral transcriptional read-through in keratinocytes transduced with self-inactivating lentiviral vectors | Q42692898 | ||
| Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse | Q42812392 | ||
| Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences | Q44491759 | ||
| Comprehensive genomic access to vector integration in clinical gene therapy | Q45855528 | ||
| Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection | Q45868390 | ||
| Site-specific integration and tailoring of cassette design for sustainable gene transfer. | Q45872654 | ||
| High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). | Q45873348 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | transcriptome | Q252857 |
| P304 | page(s) | 1667-1676 | |
| P577 | publication date | 2012-04-23 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations | |
| P478 | volume | 122 |
| Q37183068 | A comparison of foamy and lentiviral vector genotoxicity in SCID-repopulating cells shows foamy vectors are less prone to clonal dominance |
| Q38918083 | A minimal ubiquitous chromatin opening element (UCOE) effectively prevents silencing of juxtaposed heterologous promoters by epigenetic remodeling in multipotent and pluripotent stem cells |
| Q91520228 | Aberrant Clonal Hematopoiesis following Lentiviral Vector Transduction of HSPCs in a Rhesus Macaque |
| Q38772068 | Alpharetroviral self-inactivating vectors produced by a superinfection-resistant stable packaging cell line allow genetic modification of primary human T lymphocytes |
| Q36659242 | Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing |
| Q47136431 | An RNA-targeted therapy for dystrophic epidermolysis bullosa |
| Q38073294 | Biosafety features of lentiviral vectors |
| Q38127512 | Cancer gene discovery: exploiting insertional mutagenesis |
| Q33552027 | Concise review: lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases |
| Q34576925 | Deletion of the LTR enhancer/promoter has no impact on the integration profile of MLV vectors in human hematopoietic progenitors |
| Q38057725 | Development of gene therapy for thalassemia |
| Q34904038 | Differentiated neuroprogenitor cells incubated with human or canine adenovirus, or lentiviral vectors have distinct transcriptome profiles |
| Q34462660 | Efficient Transduction of LEDGF/p75 Mutant Cells by Gain-of-Function HIV-1 Integrase Mutant Viruses. |
| Q37718218 | Engineering of PEDF-Expressing Primary Pigment Epithelial Cells by the SB Transposon System Delivered by pFAR4 Plasmids |
| Q36698269 | Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy |
| Q45875615 | Ex Vivo Selection of Transduced Hematopoietic Stem Cells for Gene Therapy of β-Hemoglobinopathies |
| Q26859020 | Foamy virus vectors for HIV gene therapy |
| Q36071452 | Gene activity in primary T cells infected with HIV89.6: intron retention and induction of genomic repeats. |
| Q92283987 | Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges |
| Q26772109 | Gene therapy: progress and predictions |
| Q35913759 | Gene therapy: too much splice can spoil the dish |
| Q35878409 | Generation of a stable packaging cell line producing high-titer PPT-deleted integration-deficient lentiviral vectors |
| Q33891707 | Genome-wide analysis of alpharetroviral integration in human hematopoietic stem/progenitor cells. |
| Q35413268 | Genomic analysis of Sleeping Beauty transposon integration in human somatic cells |
| Q39237421 | Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side |
| Q40050048 | HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells. |
| Q37066334 | Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy |
| Q28077919 | Identifying Cancer Driver Genes Using Replication-Incompetent Retroviral Vectors |
| Q38111096 | Immune modulation by genetic modification of dendritic cells with lentiviral vectors. |
| Q39042960 | In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells |
| Q38264568 | Integration site and clonal expansion in human chronic retroviral infection and gene therapy. |
| Q38147100 | Lentiviral vectors for cancer immunotherapy and clinical applications |
| Q57493528 | Multiple Integrated Non-clinical Studies Predict the Safety of Lentivirus-Mediated Gene Therapy for β-Thalassemia |
| Q37690474 | No impact of lentiviral transduction on hematopoietic stem/progenitor cell telomere length or gene expression in the rhesus macaque model. |
| Q33903154 | Novel principles of gamma-retroviral insertional transcription activation in murine leukemia virus-induced end-stage tumors |
| Q37453594 | Pervasive supply of therapeutic lysosomal enzymes in the CNS of normal and Krabbe-affected non-human primates by intracerebral lentiviral gene therapy |
| Q59811369 | Pre-clinical Development of a Lentiviral Vector Expressing the Anti-sickling βAS3 Globin for Gene Therapy for Sickle Cell Disease |
| Q55165596 | Preclinical Development of a Lentiviral Vector for Gene Therapy of X-Linked Severe Combined Immunodeficiency. |
| Q37170654 | Rapid and Efficient Stable Gene Transfer to Mesenchymal Stromal Cells Using a Modified Foamy Virus Vector |
| Q54977120 | Replication-incompetent gammaretroviral and lentiviral vector-based insertional mutagenesis screens identify prostate cancer progression genes. |
| Q41857863 | Retroviral and lentiviral vectors for the induction of immunological tolerance |
| Q42820688 | Self-inactivating MLV vectors have a reduced genotoxic profile in human epidermal keratinocytes. |
| Q26767363 | Targeted approaches to induce immune tolerance for Pompe disease therapy |
| Q39154733 | Targeting Splicing in the Treatment of Human Disease |
| Q57799661 | The role of integration and clonal expansion in HIV infection: live long and prosper |
| Q36176014 | Towards a Safer, More Randomized Lentiviral Vector Integration Profile Exploring Artificial LEDGF Chimeras |
| Q37690482 | Transduction of fetal mice with a feline lentiviral vector induces liver tumors which exhibit an E2F activation signature. |
| Q28383769 | Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo |
| Q34484917 | Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy. |
| Q38714233 | Utility of next-generation RNA-sequencing in identifying chimeric transcription involving human endogenous retroviruses |
| Q38800643 | Viral Vectors: The Road to Reducing Genotoxicity |
| Q91606325 | Viral modulation of cellular RNA alternative splicing: A new key player in virus-host interactions? |
Search more.